Patent · US Active

Anti-IL13Rα2 antibodies

US11976122B2 · kind B2 · utility

0Cited by

49References

13Claims

0Family size

Assignee

ADC THERAPEUTICS SA · CH

Inventors

Patricius Hendrikus Cornelis Van Berkel · Épalinges, CH
Francois Bertelli · Royston, GB

Key dates

Filing date	Jul 30, 2021
Grant date	May 7, 2024
Priority date	—
Expiry date	Sep 14, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates to antibodies that specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13Rα2) protein, and associated uses and methods for production.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.